Literature DB >> 3112095

In-vitro activity of six fluorinated quinolones against Mycobacterium tuberculosis.

O G Berlin, L S Young, D A Bruckner.   

Abstract

Thirty-five clinical isolates of Mycobacterium tuberculosis, 24 susceptible and 11 resistant to conventional primary antituberculous drugs, were tested against six new quinolones. The mode MICs of isoniazid susceptible organisms on 7H11 agar for ciprofloxacin, ofloxacin, enoxacin, norfloxacin, CI-934 and A56620 were 1.0, 1.0, 2.0, 2.0, 1.0 and 1.0 mg/l, respectively. Strains resistant to isoniazid and other antituberculous agents were usually inhibited within one dilution of these values. These new quinolones could serve as alternate therapeutic agents or they may accelerate the antimycobacterial effects of conventional chemotherapy; these hypotheses should now be tested in experimental infections.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3112095     DOI: 10.1093/jac/19.5.611

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  13 in total

Review 1.  New antituberculous drugs in development.

Authors:  Umesh G Lalloo; Anish Ambaram
Journal:  Curr HIV/AIDS Rep       Date:  2010-08       Impact factor: 5.071

Review 2.  New antituberculous drugs derived from natural products: current perspectives and issues in antituberculous drug development.

Authors:  Masayuki Igarashi; Yoshimasa Ishizaki; Yoshiaki Takahashi
Journal:  J Antibiot (Tokyo)       Date:  2017-11-01       Impact factor: 2.649

Review 3.  Mycobacteria and the new quinolones.

Authors:  D C Leysen; A Haemers; S R Pattyn
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

4.  MICs and MBCs of Win 57273 against Mycobacterium avium and M. tuberculosis.

Authors:  L B Heifets; P J Lindholm-Levy
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

Review 5.  Enoxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J M Henwood; J P Monk
Journal:  Drugs       Date:  1988-07       Impact factor: 9.546

6.  Comparison of in vitro antimicrobial susceptibilities of Mycobacterium avium-M. intracellulare strains from patients with acquired immunodeficiency syndrome (AIDS), patients without AIDS, and animal sources.

Authors:  S K Byrne; G L Geddes; J L Isaac-Renton; W A Black
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

7.  In vitro activity of the new difluorinated quinolone sparfloxacin (AT-4140) against Mycobacterium tuberculosis compared with activities of ofloxacin and ciprofloxacin.

Authors:  N Rastogi; K S Goh
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

8.  New anti-tuberculosis agents amongst known drugs.

Authors:  Kathryn E A Lougheed; Debra L Taylor; Simon A Osborne; Justin S Bryans; Roger S Buxton
Journal:  Tuberculosis (Edinb)       Date:  2009-08-20       Impact factor: 3.131

9.  Fluoroquinolone resistance in Mycobacterium tuberculosis: an assessment of MGIT 960, MODS and nitrate reductase assay and fluoroquinolone cross-resistance.

Authors:  Rose A Devasia; Amondrea Blackman; Carolyn May; Svetlana Eden; Teresa Smith; Nancy Hooper; Fernanda Maruri; Charles Stratton; Ayumi Shintani; Timothy R Sterling
Journal:  J Antimicrob Chemother       Date:  2009-03-28       Impact factor: 5.790

10.  Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure.

Authors:  Rose A Devasia; Amondrea Blackman; Tebeb Gebretsadik; Marie Griffin; Ayumi Shintani; Carolyn May; Teresa Smith; Nancy Hooper; Fernanda Maruri; Jon Warkentin; Ed Mitchel; Timothy R Sterling
Journal:  Am J Respir Crit Care Med       Date:  2009-05-29       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.